Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Vamorolone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 26,041Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AGAMREE Shows Long-Term Safety, Efficacy in Duchenne Disease
    AGAMREE Shows Long-Term Safety, Efficacy in Duchenne Disease

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251502/0/en/AGAMREE-vamorolone-Data-Presented-at-MDA-2026-Confirm-Comparable-Long-Term-Effectiveness-for-up-to-8-Years-of-Treatment-with-Clinically-Meaningful-Safety-Advantages-in-Duchenne-Mus.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Catalyst Pharma Presents Duchenne Muscular Dystrophy Data
    Catalyst Pharma Presents Duchenne Muscular Dystrophy Data

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3251009/13009/en/Catalyst-Pharmaceuticals-to-Showcase-Real-World-Findings-in-Duchenne-Muscular-Dystrophy-and-Host-Vamorolone-Focused-Symposium-at-the-2026-MDA-Clinical-Scientific-Conference.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Santhera Proposes AGAMREE® Inclusion In Spain's Health System
    Santhera Proposes AGAMREE® Inclusion In Spain's Health System

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246266/0/en/Santhera-Announces-Proposed-Inclusion-and-Reimbursement-of-AGAMREE-Vamorolone-within-Spain-s-National-Health-System-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    Santhera Proposes AGAMREE Inclusion In Spain's Health System
    Santhera Proposes AGAMREE Inclusion In Spain's Health System

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246266/0/en/Santhera-Announces-Proposed-Inclusion-and-Reimbursement-of-AGAMREE-Vamorolone-within-Spain-s-National-Health-System-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share
    Santhera Secures Swissmedic Approval for AGAMREE in DMD
    Santhera Secures Swissmedic Approval for AGAMREE in DMD

    15 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/15/3219228/0/en/Santhera-Receives-Swissmedic-Approval-of-AGAMREE-Vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html

    GLOBENEWSWIRE
    15 Jan 2026
    Share Share
    Nxera Pharma Licenses Vamorolone For Duchenne Muscular Dystrophy
    Nxera Pharma Licenses Vamorolone For Duchenne Muscular Dystrophy

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215065/0/en/Nxera-Pharma-Licenses-Japan-and-Select-Asia-Pacific-Rights-to-Vamorolone-for-Duchenne-Muscular-Dystrophy-from-Santhera-Pharmaceuticals.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.